Moreover, given the encouraging results of new PCa target therapies that are based on PSMA recognition, i.e., ADC therapies [19] or immunological therapies [20], the availability of PSMA-tracking reagents that act as predictive biomarkers for patient selection and management helping to assess treatment response and biochemical recurrence, could be of interest. Here, FOLH1 is linked to posterior cortical atrophy.